394 related articles for article (PubMed ID: 34900707)
1. Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.
Xiong A; Wang J; Zhou C
Front Oncol; 2021; 11():757993. PubMed ID: 34900707
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
4. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
5. Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer.
Wang F; Xia T; Li Z; Gao X; Fang X
Front Oncol; 2023; 13():1213297. PubMed ID: 37727216
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review.
Olivares-Hernández A; González Del Portillo E; Tamayo-Velasco Á; Figuero-Pérez L; Zhilina-Zhilina S; Fonseca-Sánchez E; Miramontes-González JP
Ann Transl Med; 2023 Aug; 11(10):354. PubMed ID: 37675322
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Mignard X; Chaabane N; Fallet V; Wislez M
Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
12. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Leapman MS; Presley CJ; Zhu W; Soulos PR; Adelson KB; Miksad RA; Boffa DJ; Gross CP
JAMA Netw Open; 2020 Jun; 3(6):e207205. PubMed ID: 32511721
[TBL] [Abstract][Full Text] [Related]
13. Research advances in immune checkpoint drugs for non-small cell lung cancer.
Shen Y; Chen J; Li XP
J Drug Target; 2023 Aug; 31(7):700-713. PubMed ID: 37417910
[No Abstract] [Full Text] [Related]
14. Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment.
Glode AE; May MB
Am J Health Syst Pharm; 2021 Apr; 78(9):769-780. PubMed ID: 33580648
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
16. Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China.
Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
Front Oncol; 2022; 12():859938. PubMed ID: 35392244
[TBL] [Abstract][Full Text] [Related]
17. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
Huang Z; Su W; Lu T; Wang Y; Dong Y; Qin Y; Liu D; Sun L; Jiao W
Front Pharmacol; 2020; 11():578091. PubMed ID: 33117170
[TBL] [Abstract][Full Text] [Related]
18. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
Akanda ZZ; Neeson PJ; John T; Barnett S; Hanna GG; Miller A; Jennens R; Siva S
Transl Lung Cancer Res; 2021 Jun; 10(6):2766-2778. PubMed ID: 34295676
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
20. The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study.
Zhang C; Shao J; Tang X; Wu J; Li P; Li W; Wang C
Int Immunopharmacol; 2024 Jun; 134():112152. PubMed ID: 38761777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
